| 18.02 0.83 (4.83%) | 01-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.5 |
1-year : | 25.17 |
| Resists | First : | 19.26 |
Second : | 21.54 |
| Pivot price | 17.94  |
|||
| Supports | First : | 15.57 |
Second : | 12.96 |
| MAs | MA(5) : | 17.1 |
MA(20) : | 18.55 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 25.6 |
D(3) : | 21.7 |
| RSI | RSI(14): 52.3 |
|||
| 52-week | High : | 21.54 | Low : | 12.23 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MPLT ] has closed below upper band by 48.3%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 19.01 - 19.08 | 19.08 - 19.16 |
| Low: | 16.98 - 17.05 | 17.05 - 17.13 |
| Close: | 17.88 - 18 | 18 - 18.14 |
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. MapLight Therapeutics, Inc. was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California. MapLight Therapeutics, Inc operates as a subsidiary of Catalyst4, Inc.
Fri, 09 Jan 2026
MapLight Therapeutics stock rises after accelerating clinical trial timelines By Investing.com - Investing.com South Africa
Fri, 09 Jan 2026
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 - The Manila Times
Tue, 23 Dec 2025
MapLight’s phase 2 Alzheimer’s psychosis trial marks a key milestone for MPLT investors - MSN
Fri, 07 Nov 2025
MPLT Stock Price and Chart — NASDAQ:MPLT - TradingView — Track All Markets
Wed, 05 Nov 2025
Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More - 24/7 Wall St.
Mon, 27 Oct 2025
Biotech MapLight Jumps 8% in First US IPO Using Shutdown Fix - Bloomberg.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 45 (M) |
| Shares Float | 232 (M) |
| Held by Insiders | 50.7 (%) |
| Held by Institutions | 8.7 (%) |
| Shares Short | 959 (K) |
| Shares Short P.Month | 407 (K) |
| EPS | -2.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.45 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -113 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -7.27 |
| PEG Ratio | 0 |
| Price to Book value | -40.05 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|